Insights

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, evaluates the potential value of measurable residual disease as a predictive variable for multiple myeloma.

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Ajai Chari, MD, shares his insights on the role of CD38 monoclonal antibodies and bispecific antibodies for the treatment of patients with multiple myeloma.

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Michael Green, PhD, discusses the role of epigenetic therapies in treating lymphoma.

Eliza A Hawkes, MD, shares some of the rapidly evolving treatment approaches for mantle cell lymphoma, including chemotherapy-free options and assessing responses through measurable residual disease technologies.

At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.

At the Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL). 

During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.

During a debate at the 2023 Lymphoma, Leukemia & Myeloma Congress, Adriana Rossi, MD, discussed whether CAR-T therapy is more beneficial than stem cell transplant in treatment regimens among patients with multiple myeloma.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Dan Vogl, MD, discusses the optimal use of newly available bispecific T-cell engagers and other targets for multiple myeloma treatment.

During the 2023 Lymphoma, Leukemia & Myeloma Congress, Faith E Davies, MD, discussed current treatment options for patients with early relapsed multiple myeloma.